MAPT and Alzheimer disease: Based on the system pharmacology analysis of quercetin target genes, and the results of the network and functional enrichment analysis, six genes, including MAPT, PIK3R1, CASP8, DAPK1, MAPK1, and CYCS, were selected to validate the AD treatment effects of the quercetin.